Mn Services Vermogensbeheer B.V. Raises Stock Holdings in AbbVie Inc. $ABBV

Mn Services Vermogensbeheer B.V. raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 522,459 shares of the company’s stock after purchasing an additional 7,100 shares during the period. AbbVie makes up approximately 1.0% of Mn Services Vermogensbeheer B.V.’s investment portfolio, making the stock its 20th biggest position. Mn Services Vermogensbeheer B.V.’s holdings in AbbVie were worth $136,670,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. State Street Corp increased its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the period. Legal & General Group Plc acquired a new position in shares of AbbVie during the second quarter worth $2,905,952,000. Deutsche Bank AG increased its stake in shares of AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares during the period. Finally, Amundi raised its position in shares of AbbVie by 2.4% during the first quarter. Amundi now owns 10,698,095 shares of the company’s stock worth $2,326,728,000 after acquiring an additional 247,689 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook.
• Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Scotiabank increased their target price on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research report on Tuesday. Citigroup raised their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Guggenheim upped their price target on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Finally, Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and upped their target price for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $276.64.

AbbVie Price Performance

NYSE ABBV opened at $272.20 on Friday. The stock has a market capitalization of $480.92 billion, a PE ratio of 76.89, a P/E/G ratio of 1.23 and a beta of 0.24. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $274.94. The company’s 50 day simple moving average is $258.56 and its two-hundred day simple moving average is $236.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the firm posted $2.97 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts anticipate that AbbVie Inc. will post 14.01 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is currently 195.48%.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.